Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study—authors’ response

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2020-12, Vol.75 (12), p.3699-3700
Hauptverfasser:	Katlama, Christine, Assoumou, Lambert, Valantin, Marc-Antoine, Soulié, Cathia, Martinez, Esteban, Béniguel, Lydie, Bouchaud, Olivier, Raffi, François, Molina, Jean-Michel, Fellahi, Soraya, Peytavin, Gilles, Marcelin, Anne-Geneviève, Kolta, Sami, Capeau, Jacqueline, Gibowski, Severine, Cardon, Fanny, Reynes, Jacques, Costagliola, Dominique
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents Anti-HIV Agents - therapeutic use HIV Infections HIV Infections - drug therapy Human health and pathology Humans Infectious diseases Life Sciences Microbiology and Parasitology Nitriles Pharmaceutical sciences Pharmacology Pyridazines Pyridazines - therapeutic use Pyrimidines Raltegravir Potassium Raltegravir Potassium - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!